ClinicalTrials.gg
RecruitingNCT07383324Updated Apr 23, 2026

Heat Stress in Individuals With Schizophrenia

An interventional study of Simulated exposure to indoor overheating in Heat Stress, Physiological Stress and Cognitive Change, sponsored by University of Ottawa. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by University of Ottawa · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Schizophrenia is a severe mental illness affecting approximately 24 million people worldwide and is associated with more than double the all cause mortality risk of the general population. Emerging evidence demonstrates that elevated temperatures acutely worsen mental health symptoms and significantly increase the risk of heat related morbidity and mortality. For people living with schizophrenia, prolonged exposure to heat can exacerbate psychiatric symptoms, impair judgment and decision making, and reduce the ability to engage in protective behaviors such as increasing hydration, reducing clothing, improving ventilation, or seeking cooler environments. As a result, individuals with schizophrenia may experience higher rates of heat related illness. To date our understanding of heat exposure effects in individuals with schizophrenia remains incomplete, hindering the development of evidence-based strategies to protect them.

Thus, the primary objective of this exploratory study is to gather preliminary data on the effects of indoor overheating on physiological responses (core body temperature and cardiovascular function), cognitive performance (attention, working memory, and reaction time), and mood in adults with schizophrenia. Specifically, we will assess whether maintaining indoor conditions at the upper recommended temperature limit for older adults (26°C, 45% relative humidity [RH]; PMID: 38329752) is sufficient to mitigate physiological strain compared with exposure to a hot indoor environment (36°C, 45% RH) representative of non-air-conditioned homes during extreme heat events in individuals with schizophrenia. In both conditions, the individual will remain seated at rest while wearing light clothing (t shirt and shorts), with the exception of performing 15 minutes of stepping exercise (4-4.5 METS) each hour (excluding the lunch period) to reflect typical daily activities of daily living.

02

Conditions studied

  • Heat Stress
  • Physiological Stress
  • Cognitive Change

Keywords

  • Indoor overheating
  • Indoor temperatures
  • Heat wave
  • Thermoregulation
  • Schizophrenia
  • Heat strain
  • Heat vulnerability
  • Hyperthermia
  • Mental health
  • Thermal comfort
  • Physical activity
03

In context

Heat Stress Disorders

118 studies on the registry are indexed under Heat Stress Disorders; 45 are open to participants now.

This study's planned enrollment of 10 is below the median of 24 across 104 interventional studies indexed under Heat Stress Disorders.

Browse Heat Stress Disorders studies →

Lead sponsor

University of Ottawa is the lead sponsor of 125 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English or French speaking.
  • Ability to provide .
  • Individuals with and without schizophrenia or schizoaffective disorder.

Exclusion criteria

Exclusion Criteria:

  • Endurance exercise training (greater than 3 sessions of vigorous exercise training per week for 30 minutes or more)
  • Restrictions to physical activity
  • Any history of diagnoses for other psychiatric disorders deemed to make participation in the study inadvisable.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Exposure to indoor temperature upper limit of 26°C

    Participants exposed daylong (6 hours) to an indoor temperature maintained at 26°C and 45% relative humidity (humidex equivalent of 29).

    Other: Simulated exposure to indoor overheating

  • Experimental
    Exposure to hot indoor environment of 36°C

    Participants exposed daylong (6 hours) to an indoor temperature maintained at 36°C and 45% relative humidity (humidex equivalent of 45).

    Other: Simulated exposure to indoor overheating

Interventions

  • OtherSimulated exposure to indoor overheating

    Individuals with schizophrenia exposed to a 6-hour simulated heat exposure

06

What researchers measure

Primary outcomes

  1. Core temperature (Peak) during daylong exposure to indoor overheating

    Peak core (indexed by visceral temperature) temperature (15 min average) during exposure. Visceral temperature is measured continuously throughout the 6 hour exposure to the simulated indoor overheating.

    Time frame: End of 6 hour daylong exposure

Secondary outcomes

  1. Profiles of Mood States (POMS) during daylong exposure to indoor overheating

    Potential changes in mood (7 subscales of mood: tension, anger, depression, fatigue, confusion, vigor and esteem related affect). The POMS-40 is a validated, self-administered questionnaire that examines seven distinct aspects of mood state across two positive subscales (Esteem-Related Affect, and Vigor) and five negative subscales (Fatigue, Tension, Confusion, Anger, and Depression), which are described across 40 distinct adjectives. For each individual item, participants are asked to describe "how you feel right now" by responding using a 5-point Likert scale (0 = "Not at all", 1 = "A little", 2 = "Moderately", 3 = "Quite a lot", or 4 = "Extremely"). The values of items associated with a specific subscale (e.g., Fatigue) are summed to calculate its score.

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  2. Environmental Symptoms Questionnaire (ESQ) during daylong exposure to indoor overheating

    Self-reported environmental reactions and medical symptomatology associated with prolonged heat exposure. The ESQ-IV is a validated 68-item, self-administered questionnaire that has been used successfully in identifying symptomatology during exposure to a wide variety of environmental conditions, including heat exposure. Participants are asked to assess and described "how you have been feeling today" by responding to each item using a 6-point Likert scale (0 = "Not at all", 1 = "Slight", 2 = "Somewhat", 3 = "Moderate", 4 = "Quite a bit", or 5 = "Extreme"). Total Symptom Score is calculated from this data by taking the sum of the intensity ratings from all 68 individual items using reverse scores for the three positive items from the list ("I Felt Good", "I Felt Alert", and "I Felt Wide Awake").

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  3. Perceived exertion scale during daylong exposure to indoor temperature limit.

    Perceived exertional assessed via an ordinal scale ("How hard are you working?") ranging from "no exertional at all" to "maximal exertion"

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  4. Activity levels (total steps taken) during daylong exposure to indoor overheating

    Activity levels, quantified by number of steps taken per hour and totaled for each 6 hour exposure, assessed via a wearable accelerometer worn on the wrist and hip.

    Time frame: End of 6 hour daylong exposure

  5. Feel good scale during daylong exposure to indoor overheating

    Feel good scale assessed via an ordinal scale (How good do you feel?) ranging from "very good" to "very bad" (midpoint: neutral)

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  6. Thirst sensation scale during daylong exposure to indoor overheating

    Thirst sensation assessed via an ordinal scale ranging from very, very thirsty to not thirsty at all.

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  7. Thermal comfort scale during daylong exposure to indoor overheating

    Thermal comfort assessed via an ordinal scale ("How comfortable does your body temperature feel?") ranging from "very uncomfortable" to "comfortable".

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  8. Thermal sensation 2 scale during daylong exposure to indoor overheating

    Thermal sensation assessed via an ordinal scale ("How do you feel?") ranging from "hot" to "cold" (midpoint: neutral)

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  9. Thermal sensation scale during daylong exposure to indoor overheating

    Thermal sensation assessed via an ordinal scale (How hot do you feel?) ranging from "extremely hot" to "neutral".

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  10. Fluid loss during daylong exposure to indoor overheating

    Fluid loss calculated as the change in body mass during each exposure presented as a percentage of baseline body mass (corrected for food consumption).

    Time frame: At end of 6 hour daylong exposure

  11. Fluid consumption during daylong exposure to indoor overheating

    Average hourly fluid consumption calculated by weighing participant water intake at the start and end of each hour of exposure (normalized to the exposure duration).

    Time frame: At end of 6 hour daylong exposure

  12. Hydration status during daylong exposure to indoor overheating

    Hydration status measured via assessing the urine specific gravity of a urine sample.

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  13. BTrackS Balance Assessment during daylong exposure to indoor overheating (postural stability).

    To assess postural stability, participants will be asked to stand on a BTracks force plate with their feet spread out to shoulder width, hand on their hips and eyes closed. The assessment will comprise of four trials (one practice trial) lasting 20 seconds in length and 20 seconds between trials. Center of pressure (COP) vector data along vertical (y) and horizontal (x) axes will be summed for the total path excursion length (cm) during each trial

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  14. Executive function during daylong exposure to indoor overheating (cognitive function).

    Participants will be provided with a tablet device with the Sway Medical testing platform for the assessment of executive function. Participants will complete the Cued Stroop test, in which they are presented a sequence of congruent, neutral and incongruent color-word tasks.

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  15. CDC 4-Stage Balance Test during daylong exposure to indoor overheating (postural stability).

    To assess postural stability, participants hold a tablet to their chest, then auditory cues guide participants through four consecutive stances, feet side by side, instep of one foot touching the big toe of the other foot, tandem stand with one foot in front of the other, heel touching toe, and stand on one foot. The balance assessment will be evaluated based on movement detected by an accelerometer integrated into the hardware of the tablet device (Sway Medical Inc).

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  16. Memory recall during daylong exposure to indoor overheating (cognitive function).

    Participants will be provided with a tablet device with the Sway Medical testing platform for the assessment of memory recall. Participants complete both a delayed recall test and a working memory test.

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  17. Impulse control during daylong exposure to indoor overheating (cognitive function).

    Participants will be provided with a tablet device with the Sway Medical testing platform for the assessment of impulse control. Participants will be asked to respond to both "go" and "no-go" visual cues. In response to the "go" cue, participants will initiate a movement of the device.

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  18. Reaction time during daylong exposure to indoor overheating (cognitive function).

    Participants will be provided with a tablet device with the Sway Medical testing platform for the assessment of reaction time. Participants will be asked to initiate a movement of the device in response to a visual cue.

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  19. Diastolic blood pressure during daylong exposure to indoor overheating.

    Diastolic blood pressure measured in triplicate via automated oscillometry (\~60 seconds between measures).

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  20. Systolic blood pressure during daylong exposure to indoor overheating

    Systolic blood pressure measured in triplicate via automated oscillometry (\~60 seconds between measures).

    Time frame: At the start (hour 0) and end of 6 hour daylong exposure

  21. Heart rate end of daylong exposure to indoor overheating

    Heart rate measured at hour 6 of exposure to indoor overheating (15-min average).

    Time frame: End of 6 hour daylong exposure

  22. Heart rate (AUC) during daylong exposure to indoor overheating

    Areas under the curve (AUC) of heart rate during the 6 hour exposure to the simulate indoor overheating.

    Time frame: End of 6 hour daylong exposure

  23. Heat rate (Peak) during daylong exposure to indoor overheating

    Peak heart rate (15 min average) during exposure. Heart rate is measured continuously throughout the 6 hour exposure to the simulated indoor overheating.

    Time frame: End of 6 hour daylong exposure

  24. Mean skin temperature end of daylong exposure to indoor overheating

    Mean skin temperature measured over 7 body regions at hour 6 of exposure to indoor overheating (15-min average).

    Time frame: End of 6 hour daylong exposure

  25. Mean skin temperature (AUC) during daylong exposure to indoor overheating

    Areas under the curve (AUC) of mean skin temperature as calculated over 7 body regions during the 6 hour exposure to the simulate indoor overheating.

    Time frame: End of 6 hour daylong exposure

  26. Mean skin temperature (Peak) during daylong exposure to indoor overheating

    Peak mean skin temperature (15 min average) during exposure. Mean skin temperature as calculated from skin temperature measured across 7 body regions is measured continuously throughout the 6 hour exposure to the simulated indoor overheating.

    Time frame: End of 6 hour daylong exposure

  27. Core temperature end of daylong exposure to indoor overheating

    Visceral temperature measured at hour 6 of exposure to indoor overheating (15-min average).

    Time frame: End of 6 hour daylong exposure

  28. Core temperature (AUC) during daylong exposure to indoor overheating

    Areas under the curve (AUC) of visceral temperature during the 6 hour exposure to the simulate indoor overheating.

    Time frame: End of 6 hour daylong exposure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 75 non-industry interventional studies with no phase under Heat Stress Disorders, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 18 months is above that.

Counting every sponsor, half of 75 studies reached it within 16 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Feb 3, 2026
StartActual
Nov 8, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
Jul 1, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07383324
Responsible party
Glen P. Kenny (Full Professor, University Research Chair, University of Ottawa) — Principal investigator
First posted
Feb 3, 2026
Start date
Nov 8, 2025
Primary completion
May 31, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Glen P Kenny, PhD
Contact
gkenny@uottawa.ca
613-562-5800 ext. 4282
Glen P Kenny, PhD
principal investigator · University of Ottawa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion